Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the maintenance period of the P09-004 study.~* Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open-label USL255 (Type: EXPERIMENTAL): Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).